The Bull Rankings scorecard — our quality-growth score is 65.4 / 100, built from three pillars scored 0–100: Quality 65, Growth 79, Value 55 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 13% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Regeneron sits at the intersection of high‑margin specialty drugs and a pipeline that keeps the growth engine humming. Three facts lock the case: a profit margin of 27.9 %, a free‑cash‑flow of $3.8 b in the trailing twelve months, and a revenue growth of 9.3 % YoY. These numbers are the backbone of our model’s quality‑growth score of 65.4/100, where Growth (79) eclipses Value (55). The market has priced in a 13 % per‑year free‑cash‑flow growth (in year one, slowing to 3% a year by year ten), a figure a little above the current revenue growth, close enough that our model reads the two as roughly in line. In short, Regeneron is a high‑quality compounder that has already absorbed a lot of the upside, leaving a modest but solid upside if the pipeline continues to deliver.
What the business actually is
Regeneron’s revenue engine is built around a handful of blockbuster injections. EYLEA treats wet age‑related macular degeneration and diabetic macular edema, while Dupixent tackles atopic dermatitis and asthma. Libtayo addresses metastatic or locally advanced cutaneous squamous cell carcinoma, and Praluent targets hyper‑cholesterolemia. These products dominate the company’s sales mix. Dupixent, sold with Sanofi, is now the main growth driver, while EYLEA faces growing competition from rival drugs and biosimilars. The company’s focus on eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases keeps the pipeline diversified, but the current revenue engine is largely driven by eye disease and inflammatory conditions.
Why it can (or can't) keep compounding
The moat is two‑fold. First, the 27.9 % profit margin is a clear sign of pricing power and efficient manufacturing. Second, the debt‑to‑equity of 0.09 indicates a lean balance sheet that can fund research without diluting shareholders. The beta of 0.19 shows that the stock moves far less than the market. Our model flags “Diluting shareholders” as a caution because the share count has grown on a net basis, though free cash flow of $3.8 b gives the company room to offset it. Competitors struggle to replicate the proprietary antibody‑engineering platform that underpins EYLEA and Dupixent, and the regulatory hurdles for new biologics act as a natural barrier to entry.
The valuation question
At a P/E of 20, Regeneron trades at a level that reflects the market’s expectation of sustained free‑cash‑flow growth. The reverse‑DCF suggests the stock is priced for ~13 % per‑year FCF growth (in year one, slowing to 3% a year by year ten). Compared to the 9.3 % revenue growth reported for FY YoY, the implied growth is higher but not outlandish; it assumes that the company will convert revenue growth into free‑cash‑flow growth at a similar pace. The analyst consensus of $844.87 as a one‑year target sits within the $730–$1030 range, indicating that analysts are not overly aggressive. The 52‑week high of $859.34 and low of $541 show that the current price of $807.65 is near the top of the recent range.
The bear case
The most compelling skeptic points to the middling Value pillar (55). A score near the middle signals that the stock is no bargain, leaving little room for significant upside if the pipeline stalls. If the next quarterly earnings miss the $3.8 b FCF target or if the profit margin slips below 27.9 %, the implied growth of 13 % would become unrealistic. A concrete trigger would be a debt‑to‑equity rise above 0.20, indicating that the company is taking on more leverage to fund growth, which would erode the current cash‑rich profile.
What would change our mind
- Revenue growth falling below 9.3 % YoY for two consecutive quarters would undermine the growth pillar and force a re‑evaluation of the 13 % FCF growth assumption.
- Profit margin dropping below 25 % would compress earnings and free‑cash‑flow, weakening the quality pillar.
- Debt‑to‑equity climbing above 0.15 would signal increased financial risk, eroding the current low‑leverage advantage.
If any of these thresholds are breached, the thesis would shift from a high‑quality compounder to a more cautious, value‑oriented play.